Background Many people with cancer face ongoing problems from their disease and treatments, like fatigue, reduced physical fitness, feeling anxious or down, and neuropathy. While exercise might help with these problems, most studies did not focus on tailoring exercise to address these specific complaints. Exercise programs under supervision (like with a trainer) seem to work better, but barriers for following such sessions are travel distance and time. Therefore, following an exercise program at home with a trainer guiding via video (live-remote) might be a good solution. But, it is unclear how effective this remote exercise program is for cancer patients. Goal of the study: The main goal of this study is to assess the effectiveness of a personalized, live-remote exercise intervention for cancer survivors on quality of life and the patients' main complaint. The four complaints tackled in this study are: 1) fatigue, 2) reduced physical functioning, 3) anxiety and/or depressive symptoms, and 4) neuropathy. Design of the study In the LION study, 350 cancer patients will be randomly divided into the exercise group or control group. These patients all have at least one of these complaints: 1) fatigue, 2) reduced physical functioning, 3) anxiety and/or depressive symptoms, and/or 4) neuropathy. Patients cannot participate in the study if they are already very active. The exercise group will start a 12-week exercise program right away, and the other group will wait for 12 weeks before starting. The exercise program consists of three sessions per week. Two sessions per week include aerobic training and strength training. These sessions will be followed by all patients; and aim to improve fitness and strength. The third session specifically aims at improvement of the main complaint, for example fatigue. Participants will get an app and a fitness tracker to help them stay on track with their exercises. Furthermore, patients get information on the effects of exercise for cancer patients and why exercise is important for specific complaints. Measurements The main outcomes of this study are quality of life and the main side-effect of the patient. Other measurements include all kind of patient reported outcomes (like sleep problems and pain), physical fitness, muscle strength, balance, anthropometrics, and (inflammatory) markers in blood. Conclusion: This study investigates if personalized exercises done at home, with video guidance, can make cancer survivors feel better and manage their side effects more effectively.
SUMMARY Rationale: Many cancer patients suffer from long-term treatment-related side-effects like fatigue, low physical functioning, anxiety and/or depressive symptoms, and chemotherapy-induced peripheral neuropathy (CIPN). There is convincing evidence on the beneficial effects of general exercise interventions on these side-effects. However, studies to date generally fail to specifically screen for (long-term) side-effects at baseline and tailor the intervention to these specific side-effects, although larger exercise effects are observed in patients with a high symptom burden at baseline (e.g., with higher levels of fatigue). Larger effects of exercise are also observed for supervised exercise compared to unsupervised exercise. However, two of the most common barriers for attending and complying with supervised exercise are travel distance and time. An effective approach might be to provide live-remote supervision for exercise interventions. In this scenario, patients can receive guidance from a certified exercise specialist through a video-conferencing platform such as Zoom, while performing exercises within the comfort of their own homes. Currently, the effectiveness of live-remote exercise in cancer patients has not been established. Objective: The primary objective of the LION RCT is to assess the (cost-)effectiveness of a personalized, live-remote exercise intervention for cancer survivors on Health-Related Quality of Life (HRQOL) and the participants' main, self-reported side-effect. The four side-effects targeted in this study are: 1) fatigue, 2) perceived low physical functioning in daily life, 3) anxiety and/or depressive symptoms, and 4) CIPN. Study design: The LION RCT is a randomized controlled trial with two study arms: an exercise group (12 weeks) and a wait list control group. A super umbrella design will be used, allowing us to evaluate four exercise modalities (i.e., exercise modules based on participants' main side-effect) in a wide variety of cancer survivors. Study population: For this study, 350 adult cancer survivors treated with systemic chemotherapy (≥ 12 weeks to 1 year after completion of primary treatment of invasive cancer with curative intent) will be recruited independent of their primary cancer diagnosis. Participants will have reported at least one of the following side-effects: fatigue, low physical functioning in daily life, anxiety and/or depressive symptoms, CIPN. Additionally, participants need to be relatively physically inactive, i.e., perform ≤210 minutes/week of moderate-to-vigorous leisure and sports activities. Intervention: The intervention consists of three live-remote exercise sessions per week. Participants randomized to the exercise group receive the intervention after the baseline visit and the wait list control participants after the 12-week follow-up visit. A modular approach will be used to tailor the intervention to each participant's specific main side-effect. Each participant will receive the same base module (twice a week) to address HRQOL and in addition one out of four specific modules (once a week) addressing their individual main side-effect. In addition to the live-remote training, participants will be provided with the LION app and an activity tracker (Fitbit) at the start of the intervention to support exercise beyond the supervised program, during holidays and after the end of the intervention. In addition to exercise, the intervention also has an educational component including information about general effects of exercise for cancer patients and why exercise is important for specific side-effects. We consider the provision of such education as an integral part of adequate exercise programming. After the intervention period of 12 weeks, we follow the patients until 36 weeks. In this follow-up period, also two sub studies take place: 1. Sensor-based guidance sub study (only control patients from Cologne) 2. Live-remote physical fitness and function testing (in all control patients; all sites)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
350
Live-remote exercise sessions, personalized to the patients main side-effect
University Medical Center Utrecht
Utrecht, Netherlands
RECRUITINGHealth-Related Quality of Life
Measured with the summary scale of the EORTC QLQ-C30; min 0- max 100 points; higher scores mean better quality of life
Time frame: Week 0 - Week 12
A standardized symptom score, per patient, based on the individual patient's main side-effect defined at baseline
Side-effect 1: Fatigue measured with EORTC QLQ-FA12. According to a standardization procedure the symptom score of all patients will be combined into one symptom score..
Time frame: Week 0 - Week 12
A standardized symptom score, per patient, based on the individual patient's main side-effect defined at baseline
Side-effect 2: Anxiety and depressive symptoms measured with Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). According to a standardization procedure the symptom score of all patients will be combined into one symptom score.
Time frame: Week 0 - Week 12
A standardized symptom score, per patient, based on the individual patient's main side-effect defined at baseline
Side-effect 3: Physical functioning measured with EORTC QLQ-C30 physical function scale According to a standardization procedure the symptom score of all patients will be combined into one symptom score.
Time frame: Week 0 - Week 12
A standardized symptom score, per patient, based on the individual patient's main side-effect defined at baseline
Side-effect 4: CPIN measured with EORTC QLQ-CPIN20. According to a standardization procedure the symptom score of all patients will be combined into one symptom score.
Time frame: Week 0 - Week 12
Health-related quality of life
Domains of the EORTC QLQ-C30 (except summary score)
Time frame: Week 0 - Week 36
Fatigue
Cancer-Related fatigue measured with the EORTC-FA12
Time frame: Week 0 - Week 36
Anxiety and Depression
Anxiety and depressive symptoms measured with the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)
Time frame: Week 0 - Week 36
CIPN_1
Chemotherapy-induced peripheral neuropathy measured with EORTC QLQ-CIPN-20
Time frame: Week 0 - Week 36
CIPN_2
2 items of the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Time frame: Week 0 - Week 36
Sleep
Pittsburgh Sleep Quality Index (PSQI)
Time frame: 0-36 weeks
Pain prevalence and type
EORTC QLQ-SURV100
Time frame: Week 0 - Week 36
Cognitive problems
Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)
Time frame: Week 0 - Week 36
Work limitations
Work Limitations Questionnaire (WLQ)
Time frame: Week 0 - Week 36
Body image
Body Image Scale (BIS)
Time frame: Week 0 - Week 36
Fear of cancer recurrence
EORTC QLQ-surv100
Time frame: 0-36 weeks
Habitual physical activity
Modified Godin-Shephard Leisure-Time Physical Activity Questionnaire
Time frame: Week 0 - Week 36
Aerobic capacity on bike
Steep ramp test
Time frame: Week 0 - Week 24
Aerobic capacity on step
Chester step test
Time frame: Week 0 - Week 24
Handgrip strength
Handgrip test
Time frame: Week 0 - Week 24
Upper body muscle strength
Chest press
Time frame: Week 0 - Week 24
Lower body muscle strength
Leg press
Time frame: 0-24 weeks
Sit to stand test
30 sec sit to stand test- function test
Time frame: Week 0 - Week 24
Physical function
Time Up and Go (TUG) test
Time frame: Week 0 - Week 24
Balance
Single leg stance test with open and closed eyes
Time frame: Week 0 - Week 24
Physical activity
Measured with an activity tracker (Fitbit)
Time frame: 0-36 weeks
Blood pressure
Measured twice with blood pressure device
Time frame: 0-24 weeks
Resting heart rate
Measured with blood pressure device
Time frame: Week 0 - Week 24
Weight
Weight. in KG
Time frame: Week 0 - Week 24
Height
Height in cm
Time frame: Week 0 - Week 24
Waist circumference
Waist circumference in cm
Time frame: Week 0 - Week 24
Hip circumference
Hip circumference in cm
Time frame: Week 0 - Week 24
Body composition
Fat mass and fat free mass with bio-impedance - three centers
Time frame: Week 0 - Week 24
Inflammatory state
The specific inflammatory markers (e.g., cytokines, interleukins) will be decided at the time-point of analyses to be able to include factors according to up-to-date insights and use state-of the art platforms; we will for example use the Olink PEA platform (Oncology and Inflammation Array)
Time frame: 0-12 weeks
Growth factors
The specific growth factors will be decided at the time-point of analyses to be able to include factors according to up-to-date insights and use state-of the art platforms ; we will for example use the Olink PEA platform (Oncology and Inflammation Array)
Time frame: 0-12 weeks
CRP
Blood cell count
Time frame: Week 0 - Week 12
Hemoglobin
Blood cell count
Time frame: 0-12 weeks
Leucocyte counts
Blood cell count
Time frame: 0-12 weeks
Quality-adjusted life years
EuroQol-5D-5L
Time frame: Week 0 - Week 36
Health-care, patient and family costs
Modified Medical Consumption Questionnaire (iMCQ)
Time frame: Week 0 - Week 36
Productivity losses
Modified Productivity Cost Questionnaire (iPCQ)
Time frame: Week 0 - Week 36
Exercise-related (serious) adverse events
Via CASTOR app before and after each session; asked at and at the study visits.
Time frame: Week 0 - Week 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.